p. 1−12
1735-367X
Vol.14/No.1
p. 13−23
1735-367X
Vol.14/No.1
p. 24−34
1735-367X
Vol.14/No.1
p. 35−50
1735-367X
Vol.14/No.1
p. 51−58
1735-367X
Vol.14/No.1
100×103μL (68.4% and 52.4%, respectively). Conclusion: Our findings showed a lack of association of the studied polymorphisms with the risk of ALL. The influence of the rs1884444 polymorphism on relapse rate and association of rs10889677 AA genotype with favorable prognostic factors suggest the influence of the studied polymorphisms on ALL response to therapy and prognosis.]]>
p. 59−72
1735-367X
Vol.14/No.1
p. 73−80
1735-367X
Vol.14/No.1
p. 81−88
1735-367X
Vol.14/No.1
p. 89−89
1735-367X
Vol.14/No.1